Venture
from24/7 Wall St.
4 days agoKymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss
Kymera Therapeutics advanced the first IRF5-directed therapy into human trials and progressed KT-621, an oral STAT6 degrader showing efficacy comparable to dupilumab with potential to treat millions of undertreated Type 2 inflammatory disease patients.